Mannkind vor Explosion?

Seite 1 von 5
neuester Beitrag:  25.04.18 06:59
eröffnet am: 28.03.17 10:21 von: martin30sm Anzahl Beiträge: 113
neuester Beitrag: 25.04.18 06:59 von: Magnetfeldfredy Leser gesamt: 14497
davon Heute: 15
bewertet mit 2 Sternen

Seite:  Zurück   1  |  2  |  3  |  4  |  5    von   5     
28.03.17 10:21 #1 Mannkind vor Explosion?
Wie geht es weiter? Meinungen dazu?  
Seite:  Zurück   1  |  2  |  3  |  4  |  5    von   5     
87 Postings ausgeblendet.
25.02.18 14:09 #89 Steigen immer mehr ein und wollen Gewinne ma.
26.02.18 16:33 #90 jo
alles mit Ansage hier ,und morgen kein halt mehr...  
26.02.18 20:46 #91 Morgen POSITIVE NEWS erwartet
27.02.18 15:37 #92 Spannend, spannend....
 
27.02.18 16:04 #93 hi
wann kommen die news  
27.02.18 17:19 #94 Time
MannKind wird nach dem Börsenschluss am Dienstag, den 27. Februar, seine Gewinnzahlen bekannt geben.

Siehe meinen link vorher  
27.02.18 22:26 #95 News
MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results
Datum : 27/02/2018 @ 22h01
Quelle : GlobeNewswire Inc.
Name : Mannkind Corp. (MNKD)
Kurs : 3.16  -0.11 (-3.36%) @ 22h09
Mannkind Corp. share price Chart Reports Trades Level2
                    §
MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results
Mannkind Corp. (NASDAQ:MNKD)
Intraday Stock Chart

Heute : Dienstag 27 Februar 2018
Click Here for more Mannkind Corp. Charts.

MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2017.

Fourth Quarter 2017 Results

For the fourth quarter of 2017, Afrezza net revenue was $4.5 million, an increase of 125% compared to the third quarter of 2017 and 238% compared to the fourth quarter of 2016.  Included in the fourth quarter net revenue is a favorable adjustment for a change in estimate of $1.4 million. The change in estimate relates to obtaining new and more comprehensive data regarding the inventory in the distribution channel – specifically inventory in the retail channel.  This data indicated that the amount of inventory in the distribution channel was less than had been previously estimated using syndicated prescription data.  As of December 31, 2017, the amount of Afrezza shipped to wholesale and retail channels, but not yet recognized as net revenue, was $3.0 million, the same amount as September 30, 2017. A reconciliation of gross to net revenues can be found in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of the form 10-K for the year ended December 31, 2017.

Cost of goods sold was $5.0 million in the fourth quarter of 2017 compared to $4.6 million in the third quarter of 2017 and $1.6 million in the fourth quarter of 2016, an increase of $0.4 million and $3.4 million respectively.  Cost of goods sold during these periods is greater than the associated product sales due to the under-utilization of our manufacturing facility.

Research and development expenses were $3.5 million in the fourth quarter of 2017 compared to $4.4 million in the third quarter of 2017.  The $0.9 million decrease was primarily due to a $0.6 million decrease in clinical study expenses and a $0.4 million decrease in compensation expenses.  Research and development expenses were $1.6 million in the fourth quarter of 2016, representing a period-over-period increase of $1.9 million which was primarily due to a $1.3 million increase in compensation costs, a $1.4 million increase in consultant and supply costs and a $0.3 million increase in facilities costs, all due to increased clinical studies, partially offset by a decrease of $1.0 million related to a one-time FDA submission fee for a label expansion incurred in 2016 that did not recur in 2017.

Selling, general and administrative (SG&A) expenses were $23.3 million for the fourth quarter of 2017 compared to $17.7 million for the third quarter of 2017.  The $5.6 million increase was primarily due to $5.0 million in selling expenses associated with our first direct-to-consumer television advertising campaign in the fourth quarter of 2017.  SG&A expenses in the fourth quarter of 2016 were $15.3 million representing a period-over-period increase of $8.0 million which was primarily due to the $5.0 million DTC TV campaign and growth in our commercial infrastructure.

The net loss for the fourth quarter of 2017 was $32.8 million, or $0.28 per share based on 116.5 million weighted average shares outstanding, compared to a $32.9 million net loss in the third quarter of 2017 or $0.31 per share based on 104.7 million weighted average shares outstanding.  During the fourth quarter of 2016, we had net income of $54.0 million, or $0.56 per share based on 95.7 million weighted average shares outstanding. The net income in the fourth quarter of 2016 included net collaboration revenue of $10.2 million related to our license and collaboration agreement with Sanofi and a $72.0 million gain from the extinguishment of debt owed to Sanofi pursuant to a settlement agreement.

Full Year 2017 Results

Due to the termination of the Sanofi license and collaboration agreement in early 2016 and our commencement of commercial activities for Afrezza in the third quarter of 2016, a comparative analysis for Afrezza product revenue and commercial support between the year ended December 31, 2017 and the prior year is not meaningful.

For the year ended December 31, 2017, total net revenue of $11.7 million was comprised of $9.2 million of Afrezza net revenue, $1.7 million from the net revenue of surplus bulk insulin to a third party, $0.6 million from the sale of certain oncology intellectual property, and $0.3 million from collaboration net revenue.

Research and development expenses were $14.1 million for the year ended December 31, 2017 compared to $14.9 million for the prior year. The $0.8 million decrease was primarily due to a $3.6 million decrease in research and development expenses associated with a reduction in workforce in 2016, and a one-time FDA submission fee for label expansion of $1.0 million incurred in 2016. These decreases were partially offset by a $2.5 million increase in clinical trial expenses, a $0.7 million increase in expenses incurred for the development of manufacturing improvements.

Selling, general and administrative expenses were $75.0 million for the year ended December 31, 2017 compared to $46.9 million for the prior year, an increase of $28.1 million primarily due to the creation of a commercial support infrastructure after termination of the Sanofi license and collaboration agreement.

The loss on foreign currency translation is related to our purchase commitment for insulin which is denominated in Euros.  For the year ended December 31, 2017, the loss was $13.6 million as compared to a gain of $3.4 million in the prior year, a $17.1 million change due to the unfavorable movement of the U.S. dollar-Euro exchange rate.

The net loss for the year ended December 31, 2017 was $117.3 million, or $1.13 per share based on 104.2 million weighted average shares outstanding, compared to net income for the prior year of $125.7 million, or $1.37 per share based on 92.1 million weighted average shares outstanding. The net income for the prior year included net revenue – collaboration of $171.1 million and a gain on the extinguishment of debt of $72.0 million due to the recognition of previously deferred revenue following the termination of the Sanofi license and collaboration agreement.

Cash and Cash Equivalents

Cash and cash equivalents at December 31, 2017 increased to $43.9 million compared to $22.9 million at December 31, 2016, primarily due to cash inflows of $57.7 million of net proceeds from a registered direct offering of common stock, $0.5 million through sales under the at-the-market equity offering facility, $30.6 million received from Sanofi pursuant to a settlement agreement, $16.7 million from the sale of our Valencia, CA facility, $15.4 million from a net increase of debt, and cash received from revenue of $12.5 million offset in part by commercial and general corporate spending of $95.6 million. In addition to the $43.9 million in cash and cash equivalents, the Company had $4.4 million of restricted cash at December 31, 2017 of which $3.2 million was released in January 2018 following a conversion of Facility Financing Obligation debt to equity.  The net cash used in operating activities for the fourth quarter of 2017 was $30.0 million.

2H 2017 Results vs. Guidance

   Afrezza gross revenue was $8.3 million for the six months ended December 31, 2017 compared with a range of $9-$14 million.
   Afrezza net revenue was $6.4 million for the six months ended December 31, 2017 compared with a range of $6-$10 million.
   Net cash used in operating activities was $30.0 million in the fourth quarter 2017 and $23.3 million in the third quarter 2017 totaling $53.3 million compared with a range of $48-$56 million.

Conference Call

MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 46307898. Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4630  7898#. A replay will also be available on MannKind’s website for 14 days.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.  

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind’s ability to directly commercialize pharmaceutical products. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, MannKind’s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MannKind Corporation
Condensed Consolidated Statements of Operations
(Audited)
(In thousands, except per share amounts)
 
Three months ended
December 31, Twelve months ended
December 31,
2017 2016 2017 2016
 Revenues:§
Net revenue – commercial product sales $ 4,466 $ 1,322 $ 9,192 $ 1,895
Net revenue – collaboration 63 10,184 250 171,965
Revenue – other 1 898 2,303 898

          §
Total net revenues 4,530 12,404 11,745 174,758

          §
 Expenses:§
Cost of goods sold 5,018 1,553 17,228 17,121
Cost of revenue - collaboration -- 10,230 -- 32,971
Research and development 3,507 1,559 14,118 14,917
Selling, general and administrative 23,278 15,333 74,959 46,928
Property and equipment impairment -- 1,259 203 1,259
Loss (gain) on foreign currency translation 1,564 (3,433 ) 13,641 (3,433 )
(Gain) on purchase commitments -- (2,265 (215 ) (2,265 )

          §
Total expenses 33,367 24,236 119,934 107,498

          §
(Loss) income from operations (28,837 ) (11,832 ) (108,189 ) 67,260
Other (expense) income:
Change in fair value of warrant liability -- (2,510 ) 5,488 5,369
Interest income 115 15 293 85
Interest expense on notes (2,056 ) (3,010 ) (9,494 ) (15,576 )
Interest expense on note payable to principal stockholder (1,174 ) (729 ) (3,782 ) (2,901 )
(Loss) gain on extinguishment of debt (781 ) 72,024 (1,611 ) 72,024
Other (expense) income -- 18 13 (597 )

          §
Provision for income taxes 51 -- 51 --
Net (loss) income $ (32,784 ) $ 53,976 $ (117,333 ) $ 125,664

Net (loss) income per share — basic $ (0.28 ) $ 0.56 $ (1.13 ) $ 1.37

Net (loss) income per share — diluted $ (0.28 ) $ 0.56 $ (1.13 ) $ 1.36

Shares used to compute basic net (loss) income per share 116,451 95,676 104,245 92,053

Shares used to compute diluted net (loss) income per share 116,451 96,510 104,245 92,085




MannKind Corporation
Condensed Consolidated Balance Sheets
(Audited)
(In thousands)

December 31,
      2017§ December 31,
      2016§
    Assets§
Current assets:
Cash and cash equivalents $ 43,946 $ 22,895
Restricted cash 4,409 --
Accounts receivable, net 2,789 302
Receivable from Sanofi -- 30,557
 Inventory§ 2,657 2,331
Asset held for sale -- 16,730
Deferred costs from commercial product sales 405 309
Prepaid expenses and other current assets 3,010 4,364

Total current assets 57,216 77,488
Property and equipment, net 26,922 28,927
Other assets 437 648
Total assets $ 84,575 $ 107,063

Liabilities and Stockholders’ Deficit
Current liabilities
Accounts payable $ 6,984 $ 3,263
Accrued expenses and other current liabilities 12,449 7,937
Facility financing obligation 52,745 71,339
Deferred revenue, net 3,038 3,419
Deferred payments from collaboration - current 250 1,000
Recognized loss on purchase commitments — current 12,131 5,093

Total current liabilities 87,597 92,051
Note payable to principal stockholder 79,666 49,521
Accrued interest — note payable to principal stockholder 2,347 9,281
Senior convertible notes 24,411 27,635
Recognized loss on purchase commitments — long term 97,585 95,942
Warrant liability -- 7,381
Deferred payments from collaboration – long term 500 --
Milestone rights liability and other liabilities 7,201 8,845

Total liabilities 299,307 290,656
Total stockholders’ deficit (214,732 ) (183,593 )

Total liabilities and stockholders’ deficit $ 84,575 $ 107,063
       

Company Contact:
Rose Alinaya
SVP, Investor Relations and Treasury
818-661-5000
ir@mannkindcorp.com

Primary Logo

Bookmark With :
Facebook MySpace Twitter Digg Del.icio.us StumbleUpon Reddit Google Bookmarks Newsvine Technorati Furl AIM Slashdot Yahoo
 
27.02.18 23:20 #96 238% plus zum Vorjahr und 125% zum 3.Quar.
Ist alles gut angelaufen und wird in Zukunft überproportional weiter wachsen
 
28.02.18 04:51 #97 nachboerslich im Minus
 
28.02.18 12:20 #98 tja
das sieht doch alles gut aus,aber den Amis ist es wie immer zu wenig deshalb wieder heute die Gewinnmitnahme...aaber werde dann heute auch nochmal aufstocken den die 7$ werden kommen so oder so..man munkelt von einer Übernahme evt.schon bald und das zur kursen um 7-9$....  
28.02.18 14:15 #100 D.Kendall hat
OPTIONEN (180100) zum Preis von 2.76 USD bekommen-na dann mal los!!!  
28.02.18 14:49 #101 Sind doch bei 2.76$
Er Kurs ist doch die letzte Woche schon bei dem Preis von 2.80$ dann kann es doch nur noch positiv werden.  
02.03.18 14:25 #103 Mannkind und Afrezza
Zweite Arznei in der Pipline die in klinische Studie geht:

https://finance.yahoo.com/news/...s-enrollment-phase-1-210100931.html  
03.03.18 21:47 #104 Fluch oder Segen!?
Weiß noch nicht recht was ich davon halten soll! auf der einen Seite natürlich cool, dass MNKD das nächste Produkt anstrebt. Jedoch erst in Phase 1. d.h.geht noch X-Jahre und auch dieses Produkt wird wieder die Kohle auffressen bis es auf den Markt kommt. Jedoch benötigen wir diese für Afrezza! hmm... wie weiter?  

Bewertung:

21.03.18 09:10 #106 moin zusammen
bin echt mal gespannt wan hier der Dreck endlich mal steigt,also so etwas hab ich noch nie erlebt so wie hier manipuliert wird ohne worte  
23.03.18 12:05 #107 Löschung

Moderation
Moderator: st
Zeitpunkt: 23.03.18 13:51
Aktion: Löschung des Beitrages
Kommentar: Off-Topic - Werbung für threadfremde Aktien.

 

 
29.03.18 07:34 #108 Treprostinil Technosphere
So, da hat Mannkind nun wohl eine zweite Substanz in der Mache.

Irgendwie haben die Verantwortlichen bei Mannkind ein Talent, sich mit ihrem Therapieangebot Erkrankungen auszusuchen die nicht so recht passen.

Eine Inhalation, als Applikationsweg eines Medikamentes, bei Pulmonaler Hypertonie anbieten zu wollen ist schon sehr optimistisch.

Eines der größten Probleme dieser Patienten ist die Dispnoe (Atemnot), also Kurzatmigkeit.
Dies betrifft 60-100% der Patienten, je nach Stadium der Erkrankung.

Es gibt hier zwei große Gruppen (von 5 WHO Einteilungen) bei der PH
(1.) pulmonal arteriellen Hypertonie und PH aufgrund Linksherzerkrankung.
(2.) chronisch obstruktive und fibrosierende Lungenerkrankungen die zu einer PH führt.

Wie man bei solch einem Klientel eine Therapie in Erwägung zieht, die auf eine gute Resorption des Wirkstoffes über die Atemwege angewiesen ist, kann ich nicht nachvollziehen.

Nun, warten wir´s mal ab.

Wen das Thema interessiert......
http://flexikon.doccheck.com/de/Pulmonale_Hypertonie#WHO-Einteilung

https://www.aerzteblatt.de/archiv/186048/Pulmonale-Hypertonie

http://flexikon.doccheck.com/de/...mboembolische_pulmonale_Hypertonie

 

Bewertung:
1

06.04.18 13:47 #110 ja
und wie die Idioten hier alle gleich Übertreiben echt zum Kotzen..die Amis lachen sich einen ab  
12.04.18 19:18 #111 Löschung

Moderation
Moderator: st
Zeitpunkt: 13.04.18 10:54
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 1 Tag
Kommentar: Unterstellung

 

 
25.04.18 01:20 #112 Keine Hürden von Seiten der FDA für AFREZ.
25.04.18 06:59 #113 Afrezza und Mannkind
Riesenschritt in Richtung bessere Vermarktung, bessere Versicherungsabdeckung, bessere Ärzteüberzeugung, Verpartnerung ........ die Kinderstudie ist viel einfacher..... DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 022472/S-017 SUPPLEMENT APPROVAL MannKind Corporation Attention: Robyn Walsh, M.S. Senior Manager, Regulatory Affairs One Casper Street Danbury, CT 06810 Dear Ms. Walsh: Please refer to your supplemental New Drug Application (sNDA) dated and received April 19, 2018, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Afrezza (insulin human) inhalation powder. This Prior Approval sNDA provides for proposed modifications to the approved Afrezza risk evaluation and mitigation strategy (REMS). This supplement is in response to our April 17, 2018, REMS Modification Notification letter. We have completed our review of this supplemental application. It is approved effective on the date of this letter. RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS The REMS for Afrezza (insulin human) inhalation powder was originally approved on June 27, 2014, and the most recent REMS modification was approved on April 20, 2015. The REMS consists of a communication plan and a timetable for submission of assessments of the REMS. In order to minimize burden on the healthcare delivery system of complying with the REMS, we determined that you were required to make the REMS modifications outlined in our REMS Modification Notification letter dated April 17, 2018. Communication Plan: We have determined that the communication plan is no longer necessary as an element of the REMS to ensure the benefits of Afrezza (insulin human) inhalation powder outweigh its risks because the communication plan has been completed and the most recent assessment demonstrated that the communication plan has met its goals. No further assessments are necessary to assess the current communication plan. Therefore, because the communication plan is no longer necessary to ensure the benefits of the drug outweigh the risks, a REMS is no longer required for Afrezza (insulin human) inhalation powder. Reference ID: 4252859 NDA 022472/S-017 Page 2 REQUIRED PEDIATRIC ASSESSMENTS Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because none of these criteria apply to your supplemental application, you are exempt from this requirement. REPORTING REQUIREMENTS We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). If you have any questions, call Michael G. White, Ph.D., Regulatory Project Manager, at (240) 402-6149. Sincerely, {See appended electronic signature page} Jennifer Rodriguez Pippins, M.D., M.P.H. Deputy Director for Safety Division of Metabolism and Endocrinology Products Office of Drug Evaluation II Center for Drug Evaluation and Research

Das kann der langersehnte Turnaround werden!  
Seite:  Zurück   1  |  2  |  3  |  4  |  5    von   5     
Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen:    


Bitte warten...